Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007

Morbidity and Mortality Weekly Report

Volumn 59, Issue 9, 2010, Pages 253-257

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

13 VALENT PNEUMOCOCCAL VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; PNEUMOCOCCUS VACCINE; VACCINE;

ARTICLE; HEALTH SURVEY; HUMAN; INCIDENCE; INFANT; LICENSING; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

CHILD, PRESCHOOL; HUMANS; INCIDENCE; INFANT; LICENSURE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINES, CONJUGATE;

EID: 77949281884     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. CDC. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(No. RR-9).
2. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010;201:32-41.
3. CDC. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010;59:258-61.
4. CDC. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR 2008;57:144-8.
5. Kieninger DM, Kueper K, Steul K, et al. Safety and immunologic non-inferiority of 13-valent pneumococcal conjugate vaccine compared to 7-valent pneumococcal conjugate vaccine given as a 4-dose series with routine vaccines in healthy infants and toddlers. In: Proceedings of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; October 25-28, 2008; Washington, DC. Arlington, VA: Infectious Diseases Society of America; 2008.
6. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007;26:468-72.
7. Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics 2010;125:429-36.
8. CDC. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR 2005;54:893-7.
9. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005;2:83-93
10. CDC. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine-United States, 1997-2006. MMWR 2009;58:1-4.